Cardiovascular – Renal Drugs : Hyperlipidemia
ODEHY1 “Dehypotin”40mg/tab
OMEVA4 “Mevalotin Protect tablet” 40mg/tab
適應症：1.高血脂症:對於原發性高膽固醇血症及合併高膽固醇血症與高三酸甘油脂血症之病人，在使用低脂低膽固醇及低卡路里食物療法與其他非藥物療法(如運動)後，仍不
能充份降低膽固醇之情況下，可並用Mevalotin以降低血中升高之總膽固醇與低密度脂蛋白質。2.初發性預防:對於患有高固醇血症但無明顯冠狀動脈心臟病之病人，可降低心肌梗塞之初次發作及因冠狀動脈心臟疾病致死之風險。3.再發性預防:對於曾患有明顯冠狀動脈心臟疾病之病人，可降低心肌梗塞之重複發生、因冠狀動脈心臟疾病致死、需要心臟血管重建心術、及發生中風或暫時性缺血發作之風險。
Usual dose:
Cardiovascular events prophylaxis, Reduction of risk:
Adult: 40 mg qd.
Hyperlipidemia:
Adult: initial, 40 mg qd; maintenance 40-80 mg qd.
Hypercholesterolemia, heterozygous familial:
Pediatric(8-13 yrs): 20 mg qd.
Pediatric(14-18 yrs): 40 mg qd.
Dose adjustment:
Renal impairment, hepatic failure: starting dose 10 mg qd.
Immunosuppressive therapy: 10 mg qd hs; max. 20 mg/day.
Contraindication:
Liver disease (active), pregnancy or lactation; unexplained, persistent elevation of serum transaminases.
Precaution:
discontinue treatment if myopathy is diagnosed or concomitant use with fibrates, niacin, cyclosporine, or erythromycin may increase the risk; discontinue therapy if myopathy is diagnosed or suspected, renal impairment.
Adverse effect:
Common: flu-like symptoms, GI disturbances, headache, weakness.
Serious: hepatotoxicity, rhabdomyolysis, pancreatitis.
健保使用規範：同atorvastatin。